I don’t think so. There are so many facets to this that you simply can’t get away without building a core commercial team. I am not suggesting they will need a super big team that most big pharmas assemble when they introduce a new drug to the market, but I have no doubt they will need to build a much bigger and a more dynamic team than what they currently have. Also, I am not suggesting they will struggle without these initiatives but they just won’t be able to make as big an impact that many here are dreaming of! At least not any time soon! By the way, I also don’t know how they will manage quality control, regulatory audits, and other aspects post approval.
And by the time they overcome some of these challenges and start getting real traction, you can’t discount the fact that another product may be knocking on the door (run by one of the well funded & connected outfits). So they need to keep up with the technology race too in terms of continuing to improve outcomes!
Market Data 
Markets 
AI
